Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mixing Business And Philanthropy Yields Returns For Glaxo In Africa

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline is having success with its "hybrid" approach in Africa, combining no-nonsense business with the aim of improving access to medicines there – in part through deeply discounted prices, measuring managers’ sales performances by the amount of drugs sold, rather than profits, and reinvesting in health infrastructure.

You may also be interested in...



GlaxoSmithKline Offering Free Access to Potential Malaria Compounds

In another effort to boost development of malaria medicines GlaxoSmithKline is providing free public access to its library of 13,500 compounds that have shown some activity against the disease

Antifungal Specialist F2G Gets Near $61m Financing

A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.

BetterLife/Altum Merger ‘Triggered By Early COVID-19 Promise’

Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel